P53 Protein TRIZ Cases
- Mutant p53 Co-Crystal Compounds for DNA-Binding Recovery
Hydrogen-bonding compounds from mutant p53 co-crystal structures stabilize Y220C-like variants, recover DNA binding, and trigger apoptosis.
- OmniTAC Protein Recruiters for Targeted Intracellular Modification
OmniTAC compounds link a target protein to a modifier protein to drive specific intracellular modification and reactivate disease-associated proteins.
- Peptide-Polymer Conjugate Stabilizing Alpha-Helix Structure
One-pot acryloyl polymerization stabilizes alpha-helix peptides, resolving synthesis complexity and yield issues while enabling multi-target interactions.
- p53 Gene Therapy for Broad-Spectrum Pathogen Inhibition and Fibrosis Reduction
p53 gene therapy suppresses infections and reduces tissue fibrosis by activating broad-spectrum immune responses.
- Peptidomimetic Macrocycles Stabilizing p53 Alpha-Helix
Cross-linked peptidomimetic macrocycles stabilize the p53 alpha-helix to prevent MDM2-mediated degradation and restore tumor suppressor function.
- Therapeutic Peptides Targeting Agr2-POLR2A Interaction for Cancer Treatment
Peptides block Agr2 binding to POLR2A to activate p53, enhancing chemotherapy efficacy specifically in wild-type TP53 tumors.
- Peptidomimetic Macrocycles Stabilize p53 Against HDM2 Degradation
Crosslinked peptidomimetic macrocycles prevent rapid p53 degradation by HDM2, extending half-life and enhancing apoptosis in cancer cells.